Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
2
×
boston blog main
gene therapy
life sciences
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bioinnovation capital
biolabs
bluebird bio
boston top stories
chemotherapy
clinical trials
daraprim
drug pricing
drugs
duchenne muscular dystrophy
dyne therapeutics
epipen
epipens
exome
facioscapulohumeral muscular dystrophy
generic drugs
insulin
johannes fruehauf
joshua brumm
kaleido biosciences
labcentral
life science
martin shkreli
muscular dystrophy
mylan
myotonic dystrophy type 1
national blog main
national top stories
national xcon
new york blog main
novartis
What
drug
2
×
long
2
×
ago
biotech
biotechs
considering
data
diseases
driving
dyne
early
expected
experimental
eyes
genetic
good
having
healthcare
history
humans
improved
industry
innovation
innovations
investment
ipo
ipos
life
medical
medicines
muscle
outcomes
pricing
proud
public
rare
reach
sciences
therapeutics
wide
Language
unset
Current search:
long
×
drug
×
boston
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good